Dialysis of Drugs Guide 1.8.9

The guidelines included in this application aim to offer comprehensive and easily understandable information on drug dialyzability. These guidelines have been developed by utilizing a wide range of literature sources. Despite the extensive research, there remains a lack of dialysis pharmacokinetic studies for many drugs, including newly approved medications, investigational agents, and those obtainable in other countries. It is important to note that discrepancies might exist in the available data. Furthermore, the dialysis conditions outlined in published studies may not align with current dialysis practices and technological advancements.

Variables such as the duration of dialysis, blood and dialysate flow rates, types of dialysis membranes, and whether peritoneal dialysis is continuous or intermittent can all influence drug removal rates. The guidelines make a clear distinction between conventional hemodialysis and high permeability (high-flux) hemodialysis where data on such categorizations are accessible. Notably, information on drug dialyzability with continuous renal replacement therapy (CRRT) or plasmapheresis is not provided. For detailed insights on specific drugs, users are encouraged to refer to primary literature sources.

Users are directed to visit www.renalpharmacyconsultants.com for additional background information and explanatory material to aid in interpreting the tabular data provided within the application. The website contains detailed information on factors impacting drug dialyzability and particular considerations like CRRT, plasmapheresis, and substances of abuse. Prior familiarization with these details is essential before utilizing the content of this application. Moreover, the website hosts a table featuring sieving coefficient data from both in vitro and in vivo assessments, which can be instrumental in predicting dosing requirements in CRRT. Another table on the removal of substances of abuse is also available.

To access the application data, users must subscribe to an auto-renewing one-year plan. The subscription will renew automatically unless canceled at any point.

Terms of Service: https://www.apple.com/legal/internet-services/itunes/dev/stdeula/